medigraphic.com
ISSN 0185-6014 (Print)
Órgano oficial de difusión de la Federación Mexicana de Patología Clínica, AC y de la Asociación Latinoamericana de Patología Clínica/Medicina de Laboratorio

2001, Number 4

<< Back Next >>

Rev Mex Patol Clin Med Lab 2001; 48 (4)

Anthrax. Microbiology, epidemiology, clinical manifestations, diagnosis, prevention and treatment

Barriga AG, Giono CS, Osorio CL

Language: Spanish
References: 26
Page: 203-209
PDF size: 122.86 Kb.


ABSTRACT

For centuries, anthrax has caused disease, in animals and, un- commonly, serious illness in humans, research on anthrax as biological weapon began more than 80 years ago, of the numerous biological agents that may be used as weapons, anthrax is one of the most serious. In 1970 a World Health Organization Expert Committe, estimated the casualties following the theorical aircraft release of 50 kg of anthrax spores over a developed urban population of 500,000, would be 125,000, 95,000 of whom would be expected to die without treatment. To develop a maximally effective response to a bioterrorist incident involving anthrax, the medical community will require knowledge of the organism, its genetics, pathogenesis, prophylactic and therapeutic regimens, and the support of the clinical laboratory. If the laboratory has been alerted to the possibility of anthrax, gram stains, biochemical testing and review of colonial morphology should provide a preliminary diagnosis 12 to 24 hours late. Definitive diagnosis would require an additional 1 to 2 day of testing in a reference laboratory. In this review we analized the microbiology, pathogenesis, clinical manifestations, epidemiology, diagnosis, prevention and therapy of anthrax.


REFERENCES

  1. Éxodo 9:1-12.

  2. Flambleton P, Turnbull PCB. Anthrax vaccine development a continuing story. In: Bacterial vaccines. New York: A Liss Inc., 1990: 105-122.

  3. Pasteur L, Chamberlain CE, Roux E. Compte rendu sommaire des experiences faites a lovilly –le- Fort, pares Melon, sur la vaccination charbonneuse. Comptes pendus des sciences de L. Academie des Sciences 1881;1(92):1378-1383.

  4. Tumer M. Anthrax in humans in Zimbawe Cent. Afr J Med 1980; 26: 160-161.

  5. Report of a W.H.O. group of consultants. Health aspects of chemical and biological weapons. Geneva: World Health Organization, 1970: 97-99.

  6. Vázquez SC, Quiñones RG, Moreno R. Bacilos gramm positivos esporulados en bacteriología médica. 2ª ed. México, D.F.: Editorial Cuellar, 1999: 455-472.

  7. Giono CS. Diferencias entre el género Bacillus de interés médico. En: Bacteriología Médica Diagnóstica. México, D.F.: Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, 1993; 40: 229-233.

  8. Forbes ABS, Sahm DF, Neissfold SA. Bacillus and similar organisms. In: Bailey S. Diagnostic Microbiology. 10a ed. 1998; 54(9): 638-644.

  9. Kuhout E, Sehat A, Ashraf M. Anthrax: a continuous problem in South West Iran. Am J Med Sci 1964: 247-565.

  10. Titball RN, Turnbull PCB, Hutson RA. The monitoring and detection of Bacillus anthracis in the environment. Jour Applied Bacteriol 1995; 70 (Suppl): 95-185.

  11. Dragon DC, Rennie RP. The ecology of anthrax spores. Can Vet J 1995; 36: 295-301.

  12. Santhana TS, Ke N, Ezzell JW, Ahshire TG. Serological studies of patients with cutaneous and oral-pharyngeal anthrax from Northern Thailand. Am J Trop Med Hyg 1988; 39: 575-581.

  13. Brachman PS. Inhalation anthrax. Ann NY Acad Sciences 1980; 353: 83-93.

  14. Albrink WS, Brooks SM, Biron RE, Kopel M. Human inhalation anthrax. Am J Pathol 1960; 36: 457-471.

  15. Ross JM. The pathogenesis of anthrax following the administration of spores by the respiratory route. J Pathol Bacteriol 1957; 73: 485-495.

  16. Dallfort F, Kaufmann AF, Brachnon RS. Woolsorter disease. Arch Pathol 1971; 92: 418-426.

  17. Vesal K, Yeganehdoust J, Dutz W, Kohout E. Radiologic changes in inhalation anthrax. Clin Radiol 1975; 26: 471-474.

  18. Dutz W, Sardi F, Kouhout E. Gastric anthrax with massive ascites. JAMA 1970; 11: 352-354.

  19. Franz DR, Jahrling PB, Friendlendes I. Clinical recognition and management of patients exposed to biological warfore agents. JAMA 1997; 278: 399-411.

  20. Amramoud FA, Grinberg LM, Yampols Kaya O, Walker PA. Pathology of inhalational anthrax in 42 cases from the Svordlovsk outbreak in 1979. Proc Nath Acad Sci USA 1993;90:2291-2298.

  21. Manchee RJ, Stewart WD. The decontamination of Gruinard Island Chem. Br July 1988: 690-691.

  22. Doganay M, Aydin N. Antimicrobial susceptibility of Bacillus anthracis. Scand J Infect Dis 1991; 23: 333-335.

  23. Lightfoot NT, Scott RJ, Turnbull J. Antimicrobial susceptibility of Bacillus anthracis. Proceedings of the international workshop on anthrax. Salisburry Med Bull 1990; 68: 95-98.

  24. Turnbull PC. Anthrax vaccines, past, present and future. Vaccine 1991; 9: 533-539.

  25. Brachman PS, Gold H, Plotkin SA, Fekety FA, Werrin M, Ingraham WA. Field evaluation of human anthrax vaccines. Am J Public Health 1962; 52: 632-645.

  26. Walker JS, Lincoln RE, Klein F. Pathophysiological and biochemical changes in anthrax. Fed Procd 1967; 26: 1539-1544.




2020     |     www.medigraphic.com